TerminatedPhase 2NCT03705390

A Safety and Tolerability Study of ILB® in Patients With Amyotrophic Lateral Sclerosis (ALS)

Studying Amyotrophic lateral sclerosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of Birmingham
Principal Investigator
Venkataramanan Srinivasan, MRCP, MRCP
University of Birmingham
Intervention
ILB®(drug)
Enrollment
11 enrolled
Eligibility
18 years · All sexes
Timeline
20192021

Study locations (1)

Collaborators

TikoMed AB · University Hospital Birmingham · Neuregenix Ltd

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03705390 on ClinicalTrials.gov

Other trials for Amyotrophic lateral sclerosis

Additional recruiting or active studies for the same condition.

See all trials for Amyotrophic lateral sclerosis

← Back to all trials